The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular CarcinomaAkiyoshi Kinoshita, Masayuki Saruta, Yoshihiro Matsumoto et al.|In Vivo|2022Cited by 14
Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational studyAkiyoshi Kinoshita, Masayuki Saruta, Noriko Hagiwara et al.|Journal of Oncology Pharmacy Practice|2022Cited by 3